Abstract: The present invention describes the combination of topically inhaled medicinal formulations comprising an anticholinergic component and a glucocorticosteroid component and its use in the symptomatic and prophylactic treatment of diseases of the respiratory tract, especially with an obstructive component or underlying inflammation like asthma and chronic obstructive pulmonary disease (COPD). It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the NOVOLIZER®.

Abstract: The present invention relates to a nasel formulation comprising as its active ingredient an intranasal corticosteroid, and also to a method for prophylaxis or treatment of seasonal or perennial allergic and non-allergic rhinitis and rhinoconjunctivitis.

Abstract: The invention relates to pharmaceutical combinations of potassium channel openers and sodium channel inhibitors, for treating pains which are accompanied by an increase in muscle tone.

Abstract: Pharmaceutical compositions comprising an anticholinergic and at least one leukotriene inhibitor for treatment of respiratory diseases, including allergic rhinitis, bronchial asthma, COPD and common cold, and methods of treatment.

Abstract: The invention relates to novel combinations based on anticholinergics, ?2-adrenoceptor agonists, PDE 4 Inhibitors, glucocorticoids, and leukotriene-receptor antagonists, process for their production and their use for the treatment of inflammatory diseases, preferably respiratory diseases as bronchial asthma and chronic obstructive pulmonary diseases (COPD) or rheumatic or autoimmune diseases.

Abstract: The present invention relates to a combination of an inhaled/oral PDE 4 inhibitor in combination with inhaled anticholinergic bronchodilators (muscarinic receptor antagonists), preferentially Roflumilast or AWD-12-281 and R,R-glycopyrrolate, for symptomatic or prophylactic treatment of respiratory diseases, especially those accompanied by obstruction or inflammation such as chronic obstructive pulmonary disease (COPD) or asthma. It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer®.

Abstract: Novel combinations based on anticholinergics, ?2-adrenoceptor agonists, PDE 4 Inhibitors, glucocorticoids, and leukotriene-receptor antagonists, process for their production and their use for the treatment of inflammatory diseases, preferably respiratory diseases as bronchial asthma and chronic obstructive pulmonary diseases (COPD) or rheumatic or autoimmune diseases. A particular combination comprises R,R-glycopyrrolate, rolipram, and budesonide, or physiologically acceptable salts thereof, wherein dosage amounts are such that a synergistic therapeutic effect is achieved.

Abstract: The invention relates to treating colorectal polyps and precancercerous colorectal changes by topical administration of immunomodulating drugs of the imidazoquinoline family, such as imiquimod (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine), resiquimod (4-amino-?,?-dimethyl-2-ethoxymethyl-1H-imidazo[4,5-c]quinoline-1-ethanol), sotirimod (2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine).

Abstract: The present invention describes a combination of an anticholinergic, such as R,R-glycopyrrolate, and a ? mimetic, such as tormoterol, for the treatment of respiratory diseases including airway inflammation or obstruction such as chronic obstructive pulmonary disease (COPD) and asthma.

Abstract: The present invention relates to a process for the enrichment of the R,R- or S,S-configured glycopyrronium isomers and their thienyl derivatives having the R,S or S,R configuration.

Abstract: The invention relates to treating of colorectal diseases such as polyps, precancerous stages, and prevention and adjuvant treatment of colorectal cancer by topical administration of immunomodulating drugs of the imidazoquinoline family, such as imiquimod (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine), resiquimod (4-amino-?,?-dimethyl-2-ethoxymethyl-1H-imidazo[4,5-c]quinoline-1-ethanol), sotirimod (2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine).

Abstract: The subject of the present invention is to provide a combination of two centrally acting analgesics, flupirtine and tramadol, or their respective pharmaceutically acceptable salts for the treament of pain.

Abstract: The invention relates to a novel combination of a soft steroid, in particular loteprednol, and at least one ?2 adrenoceptor agonist for the simultaneous, sequential or separate treatment of allergies and/or airway disorders, medicaments comprising the combination, processes for the production of such medicaments and the use of the novel combination for the production of medicaments for the simultaneous, sequential or separate treatment of allergies and/or airway disorders.

Abstract: The present invention describes the combination of topically inhaled medicinal formulations comprising an anticholinergic component and a glucocorticosteroid component and its use in the symptomatic and prophylactic treatment of diseases of the respiratory tract, especially with an obstructive component or underlying inflammation like asthma and chronic obstructive pulmonary disease (COPD). It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer®.

Abstract: The invention relates to the use of R-(+)-?-lipoic acid in oxidised or reduced form or derivatives thereof alone or in combination with other effective compounds for the prevention of diabetes.

Abstract: The present invention describes a combination of anticholinergic and ? mimetics for the treatment of respiratory diseases including airway inflammation or obstruction such as chronic obstructive pulmonary disease (COPD) and asthma. It further comprises the preparation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer®.

Abstract: In order to improve the administration of powdered pharmaceuticals, the invention proposes a storage system for powdered pharmaceuticals, in particular for use or integration in a powder inhaler, for receiving a multiplicity of doses of at least one medically active substance, with at least two storage spaces (4) which are separate from each other and are each intended to hold a multiplicity of doses of a medically active substance, and the invention also proposes an inhaler for powdered pharmaceuticals, the inhaler comprising such a pharmaceutical powder cartridge system (1) as an integral part or as an exchangeable part.

Abstract: The invention relates to novel combinations based on anticholinergics, ?2-adrenoceptor agonists, PDE 4 Inhibitors, glucocorticoids, and leukotriene-receptor antagonists, process for their production and their use for the treatment of inflammatory diseases, preferably respiratory diseases as bronchial asthma and chronic obstructive pulmonary diseases (COPD) or rheumatic or autoimmune diseases.

Abstract: A cartridge for powdered pharmaceuticals. At least two storage spaces are provided which are separate from each other and which are each intended to hold a multiplicity of doses of a medically active substance. The storage spaces are individual cartridges which may be lockingly coupled together to form a single cartridge. Each individual cartridge has a metering cavity.

Abstract: The invention relates to a method for producing pure racemic, R- or S-thioctic acid or mixtures thereof by reacting 6,8-disubstituted octanoic acid or their salts or esters with sulfides, sulfur or sulfites.